Tali Amir
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tali Amir has a total of 48 co-authors. Here are the top co-authors by number of shared publications:
- Varadan Sevilimedu
Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY
4 shared publications - Christopher E. Comstock
Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY
3 shared publications - Janice S. Sung
Department of Radiology, Memorial Sloan Kettering Cancer Center, 300 E 66th St, New York, NY 10065
3 shared publications - Maxine S. Jochelson
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
3 shared publications Molly P. Hogan
Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, USA
3 shared publications- Noam Nissan
Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY
3 shared publications
Latest Publications
- 1 July 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 320 (1)
Contrast-enhanced Mammography for Breast Cancer Screening in Women at Increased Risk: Comparison of Prevalence and Incidence Screens
The ability of contrast-enhanced mammography to help detect cancer during prevalence screening in women at increased risk for breast cancer is maintained in subsequent incidence screens, with better specificity and accuracy.
- 1 July 2026
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 320 (1)
Contrast-enhanced Mammography for Breast Cancer Screening in Women at Increased Risk: Comparison of Prevalence and Incidence Screens
The ability of contrast-enhanced mammography to help detect cancer during prevalence screening in women at increased risk for breast cancer is maintained in subsequent incidence screens, with better specificity and accuracy.
- Open Access
- 13 June 2026
- Published by Springer Nature in European Radiology
- Vol. 36 (10) , 7864-7873
Clinical significance of lesion conspicuity on contrast-enhanced mammography
Objective: To determine if lesion conspicuity on contrast-enhanced mammography (CEM) is independently associated with malignancy. Materials and methods: This retrospective, single-institution study identified consecutive abnormal screening and diagnostic CEMs between January 2019 and December 2021. The conspicuity of enhancing lesions on CEM recombined images was graded (low, moderate, or high) by one or both breast radiologists assigned as readers for the study, blinded to two-year imaging follow-up or biopsy pathology results. The positive predictive value (PPV) for malignancy was determined for each level of conspicuity. Results: Across 476 CEM examinations in 455 women (median age, 49 years; IQR: 44–57), there were 563 enhancing lesions (55 malignant, 508 benign). Of the 563 enhancing lesions, 52% (292/563) were low conspicuity, 38% (213/563) moderate, and 10.3% (58/563) high. The PPV to predict cancer was 9% (95% CI: 6–12%), 11% (95% CI: 7–16%), and 10% (95% CI: 4–21%) for low, moderate, and high conspicuity (low vs high, p = 0.68; low vs moderate, p = 0.34; moderate vs high, p = 0.83). Of the 55 cancers, most high-conspicuity cancers presented on both recombined images and low-energy images (5/6; 83%), while most low- (21/25; 84%) and moderate-conspicuity cancers (17/24; 71%) presented on recombined images only ( p = 0.006). Inter-reader agreement was almost perfect for 100 lesions graded by both breast radiologists (κ = 0.94). Conclusion: Lesion conspicuity is not independently associated with malignancy. Most enhancing lesions, including most cancers, show low or moderate conspicuity on CEM. Key Points: Question Is lesion conspicuity on CEM, determined on the recombined images, an independent predictor of malignancy ? Findings The PPV for low, moderate, and high conspicuity to predict malignancy was 8.6%, 11.3%, and 10.3%, respectively (non-significant differences between low, moderate, and high conspicuity) . Clinical relevance Lesion conspicuity is not an independent predictor of malignancy. Enhancing lesions seen on recombined images should not be considered benign based on low conspicuity alone, as most low-conspicuity cancers presented with enhancement only and lacked a correlate finding on low-energy images .
- 13 June 2026
- Published by Springer Nature in European Radiology
- Vol. 36 (10) , 7864-7873
Open AccessClinical significance of lesion conspicuity on contrast-enhanced mammography
Objective: To determine if lesion conspicuity on contrast-enhanced mammography (CEM) is independently associated with malignancy. Materials and methods: This retrospective, single-institution study identified consecutive abnormal screening and diagnostic CEMs between January 2019 and December 2021. The conspicuity of enhancing lesions on CEM recombined images was graded (low, moderate, or high) by one or both breast radiologists assigned as readers for the study, blinded to two-year imaging follow-up or biopsy pathology results. The positive predictive value (PPV) for malignancy was determined for each level of conspicuity. Results: Across 476 CEM examinations in 455 women (median age, 49 years; IQR: 44–57), there were 563 enhancing lesions (55 malignant, 508 benign). Of the 563 enhancing lesions, 52% (292/563) were low conspicuity, 38% (213/563) moderate, and 10.3% (58/563) high. The PPV to predict cancer was 9% (95% CI: 6–12%), 11% (95% CI: 7–16%), and 10% (95% CI: 4–21%) for low, moderate, and high conspicuity (low vs high, p = 0.68; low vs moderate, p = 0.34; moderate vs high, p = 0.83). Of the 55 cancers, most high-conspicuity cancers presented on both recombined images and low-energy images (5/6; 83%), while most low- (21/25; 84%) and moderate-conspicuity cancers (17/24; 71%) presented on recombined images only ( p = 0.006). Inter-reader agreement was almost perfect for 100 lesions graded by both breast radiologists (κ = 0.94). Conclusion: Lesion conspicuity is not independently associated with malignancy. Most enhancing lesions, including most cancers, show low or moderate conspicuity on CEM. Key Points: Question Is lesion conspicuity on CEM, determined on the recombined images, an independent predictor of malignancy ? Findings The PPV for low, moderate, and high conspicuity to predict malignancy was 8.6%, 11.3%, and 10.3%, respectively (non-significant differences between low, moderate, and high conspicuity) . Clinical relevance Lesion conspicuity is not an independent predictor of malignancy. Enhancing lesions seen on recombined images should not be considered benign based on low conspicuity alone, as most low-conspicuity cancers presented with enhancement only and lacked a correlate finding on low-energy images .
- 1 May 2026
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 8 (3) , e250559
Interval Cancers after Negative Screening Contrast-enhanced Mammography
In patients undergoing screening contrast-enhanced mammography, the interval cancer rate was 2.29 cancers per 1000 examinations, and invasive interval cancers were associated with moderate or marked background parenchymal enhancement.
- 1 May 2026
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 8 (3) , e250559
Interval Cancers after Negative Screening Contrast-enhanced Mammography
In patients undergoing screening contrast-enhanced mammography, the interval cancer rate was 2.29 cancers per 1000 examinations, and invasive interval cancers were associated with moderate or marked background parenchymal enhancement.
- 1 December 2025
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 22 (12) , 1521-1525
A Pilot Study: Leveraging Mammography and Digital Outreach to Identify and Engage Women at Risk for Lung Cancer in Lung Cancer Screening
- 1 December 2025
- Published by Elsevier in Journal of the American College of Radiology
- Vol. 22 (12) , 1521-1525
A Pilot Study: Leveraging Mammography and Digital Outreach to Identify and Engage Women at Risk for Lung Cancer in Lung Cancer Screening
- 1 March 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 314 (3) , e242006
Comparison of Contrast-enhanced Mammography and Low-Energy Imaging with or without Supplemental Whole-Breast US in Breast Cancer Detection
Breast cancer detection improved with contrast-enhanced mammography compared with low-energy imaging alone or low-energy imaging with whole-breast US.
- 1 March 2025
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 314 (3) , e242006
Comparison of Contrast-enhanced Mammography and Low-Energy Imaging with or without Supplemental Whole-Breast US in Breast Cancer Detection
Breast cancer detection improved with contrast-enhanced mammography compared with low-energy imaging alone or low-energy imaging with whole-breast US.
- Open Access
- 1 March 2025
- Published by Korean Society of Ultrasound in Medicine in Ultrasonography
- Vol. 44 (2) , 145-152
Utilization of artificial intelligence to triage patients with delayed follow-up of probably benign breast ultrasound findings
Purpose: This study aimed to evaluate our institution's experience in using artificial intelligence (AI) decision support (DS) as part of the clinical workflow to triage patients with Breast Imaging Reporting and Data System (BI-RADS) 3 sonographic lesions whose follow-up was delayed during the coronavirus disease 2019 (COVID-19) pandemic, against subsequent imaging and/or pathologic follow-up results.Methods: This retrospective study included patients with a BI-RADS category 3 (i.e., probably benign) breast ultrasound assessment from August 2019–December 2019 whose follow-up was delayed during the COVID-19 pandemic and whose breast ultrasounds were re-reviewed using Koios DS Breast AI as part of the clinical workflow for triaging these patients. The output of Koios DS was compared with the true outcome of a presence or absence of breast cancer defined by resolution/stability on imaging follow-up for at least 2 years or pathology results.Results: The study included 161 women (mean age, 52 years) with 221 BI-RADS category 3 sonographic lesions. Of the 221 lesions, there were two confirmed cancers (0.9% malignancy rate). Koios DS assessed 112/221 lesions (50.7%) as benign, 42/221 lesions (19.0%) as probably benign, 64/221 lesions (29.0%) as suspicious, and 3/221 lesions (1.4%) as probably malignant. Koios DS had a sensitivity of 100% (2/2; 95% confidence interval [CI], 16% to 100%), specificity of 70% (154/219; 95% CI, 64% to 76%), negative predictive value of 100% (154/154; 95% CI, 98% to 100%), and false-positive rate of 30% (65/219; 95% CI, 24% to 36%).Conclusion: When many follow-up appointments are delayed, e.g., natural disaster, or scenarios where resources are limited, breast ultrasound AI DS can help triage patients with probably benign breast ultrasounds.
- 1 March 2025
- Published by Korean Society of Ultrasound in Medicine in Ultrasonography
- Vol. 44 (2) , 145-152
Open AccessUtilization of artificial intelligence to triage patients with delayed follow-up of probably benign breast ultrasound findings
Purpose: This study aimed to evaluate our institution's experience in using artificial intelligence (AI) decision support (DS) as part of the clinical workflow to triage patients with Breast Imaging Reporting and Data System (BI-RADS) 3 sonographic lesions whose follow-up was delayed during the coronavirus disease 2019 (COVID-19) pandemic, against subsequent imaging and/or pathologic follow-up results.Methods: This retrospective study included patients with a BI-RADS category 3 (i.e., probably benign) breast ultrasound assessment from August 2019–December 2019 whose follow-up was delayed during the COVID-19 pandemic and whose breast ultrasounds were re-reviewed using Koios DS Breast AI as part of the clinical workflow for triaging these patients. The output of Koios DS was compared with the true outcome of a presence or absence of breast cancer defined by resolution/stability on imaging follow-up for at least 2 years or pathology results.Results: The study included 161 women (mean age, 52 years) with 221 BI-RADS category 3 sonographic lesions. Of the 221 lesions, there were two confirmed cancers (0.9% malignancy rate). Koios DS assessed 112/221 lesions (50.7%) as benign, 42/221 lesions (19.0%) as probably benign, 64/221 lesions (29.0%) as suspicious, and 3/221 lesions (1.4%) as probably malignant. Koios DS had a sensitivity of 100% (2/2; 95% confidence interval [CI], 16% to 100%), specificity of 70% (154/219; 95% CI, 64% to 76%), negative predictive value of 100% (154/154; 95% CI, 98% to 100%), and false-positive rate of 30% (65/219; 95% CI, 24% to 36%).Conclusion: When many follow-up appointments are delayed, e.g., natural disaster, or scenarios where resources are limited, breast ultrasound AI DS can help triage patients with probably benign breast ultrasounds.
- 17 May 2023
- Published by Elsevier in Clinical Imaging
- Vol. 101, 77-85
A role for breast ultrasound Artificial Intelligence decision support in the evaluation of small invasive lobular carcinomas
- 17 May 2023
- Published by Elsevier in Clinical Imaging
- Vol. 101, 77-85
A role for breast ultrasound Artificial Intelligence decision support in the evaluation of small invasive lobular carcinomas
- 1 January 2021
- Published by Elsevier in European Journal of Radiology
- Vol. 134, 109407
Comparison of radiation dose between 2D digital stereotactic versus digital breast tomosynthesis-guided breast biopsies
- 1 January 2021
- Published by Elsevier in European Journal of Radiology
- Vol. 134, 109407
Comparison of radiation dose between 2D digital stereotactic versus digital breast tomosynthesis-guided breast biopsies
- 17 December 2020
- Published by SAGE Publications in Journal of Medical Screening
- Vol. 28 (3) , 311-317
Benefits of digital breast tomosynthesis: A lesion-level analysis
Objective: To compare outcome metrics of digital breast tomosynthesis (DBT) breast cancer screening with full-field digital mammogram (FFDM); specifically, to compare recall rates by the type of recalled finding, and to assess if screening with DBT versus FFDM changes biopsy recommendations and if the likelihood of malignancy varied by lesion type, if detected on DBT or FFDM screening mammogram. Methods: The outcomes of 22,055 FFDM and DBT screening mammograms were retrospectively reviewed. The exams were performed at an academic institution between August 2015 and September 2016. Performance of screening with FFDM versus DBT was compared in terms of recall rate and percentage of recalled lesions resulting in a cancer diagnosis, with subset analyses performed for specific mammographic findings. Results: The recall rate was 10.6% for FFDM and 8.0% for DBT ( p < 0.001). Architectural distortion was more likely to be recalled on DBT screening than FFDM ( p = 0.002), and was associated with an increased likelihood of malignancy ( p = 0.008). Asymmetries were less likely to be recalled on DBT than FFDM ( p < 0.001) screening mammogram, but more likely to be recommended for biopsy when detected on DBT. Calcifications more frequently required short-term follow-up or biopsy on both DBT and FFDM. Conclusions: DBT screening confers an advantage in detection of architectural distortion representing malignancy. Recall rate of asymmetries are reduced with screening DBT, probably due to reduction of tissue superimposition. Calcifications pose a particularly difficult diagnostic challenge for breast imagers, regardless of screening mammogram type.
- 17 December 2020
- Published by SAGE Publications in Journal of Medical Screening
- Vol. 28 (3) , 311-317
Benefits of digital breast tomosynthesis: A lesion-level analysis
Objective: To compare outcome metrics of digital breast tomosynthesis (DBT) breast cancer screening with full-field digital mammogram (FFDM); specifically, to compare recall rates by the type of recalled finding, and to assess if screening with DBT versus FFDM changes biopsy recommendations and if the likelihood of malignancy varied by lesion type, if detected on DBT or FFDM screening mammogram. Methods: The outcomes of 22,055 FFDM and DBT screening mammograms were retrospectively reviewed. The exams were performed at an academic institution between August 2015 and September 2016. Performance of screening with FFDM versus DBT was compared in terms of recall rate and percentage of recalled lesions resulting in a cancer diagnosis, with subset analyses performed for specific mammographic findings. Results: The recall rate was 10.6% for FFDM and 8.0% for DBT ( p < 0.001). Architectural distortion was more likely to be recalled on DBT screening than FFDM ( p = 0.002), and was associated with an increased likelihood of malignancy ( p = 0.008). Asymmetries were less likely to be recalled on DBT than FFDM ( p < 0.001) screening mammogram, but more likely to be recommended for biopsy when detected on DBT. Calcifications more frequently required short-term follow-up or biopsy on both DBT and FFDM. Conclusions: DBT screening confers an advantage in detection of architectural distortion representing malignancy. Recall rate of asymmetries are reduced with screening DBT, probably due to reduction of tissue superimposition. Calcifications pose a particularly difficult diagnostic challenge for breast imagers, regardless of screening mammogram type.